Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 1, 2023
Discovery & Translation
CorrectSequence’s hemoglobin base editor; plus Denali’s LXR agonist and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 9, 2023
Emerging Company Profile
OrsoBio: bringing obesity mechanisms to bear
Samsara-incubated company garners $60M series A to advance multi-target pipeline assembled via in-licensing
BioCentury | Jun 2, 2023
Discovery & Translation
Single-cell T cell atlas identifies new subsets; plus CoRegen’s cell therapy and more
BioCentury’s roundup of translational news
BioCentury | Jul 11, 2022
Finance
After promising ASCO readout, Inspirna raises $50M series D
Sands, Vivo lead syndicate after start-up showcases response rates for potential first-in-class therapy in colorectal cancer
BioCentury | Nov 3, 2017
Product Development
Liver X factor
How Rgenix’s liver X agonist could help overcome checkpoint resistance in cancer
BioCentury | Jun 2, 2017
Product Development
Ears wide open
How hearing loss became an investable space
Items per page:
1 - 10 of 78